Antiplatelet effects of citalopram in patients with ischaemic stroke: A randomized, placebo-controlled, double-blind study

Scientific Reports

Volumn 9, Issue 1, 2019, Pages

  Kraglund, Kristian Lundsgaard ^a,b   Mortensen, Janne Kaergaard ^a   Johnsen, Søren Paaske ^c,d   Andersen, Grethe ^a,d   Grove, Erik Lerkevang ^a,d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b VESTFOLD HOSPITAL TRUST   (Norway)

^c AALBORG UNIVERSITY   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CITALOPRAM; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

AGED; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CITALOPRAM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PLATELET AGGREGATION INHIBITORS; SEROTONIN UPTAKE INHIBITORS; STROKE;

EID: 85077311247     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-019-56487-8     Document Type: Article

References (19)

1. Mead, G. et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 11, CD009286 (2012).
2. Mortensen, J. K., Johnsen, S. & Andersen, G. Prescription and predictors of post-stroke antidepressant treatment: A population-based study. Acta Neurol Scand. 138, 235–44 (2018).
3. Vanhoutte, P. M. Platelet-derived serotonin, the endothelium, and cardiovascular disease. J Cardiovasc Pharmacol. 17, S6–12 (1991).
4. Berger, M., Gray, J. A. & Roth, B. L. The expanded biology of serotonin. Annu Rev Med. 60, 355–66 (2009).
5. Celada, P., Dolera, M., Alvarez, E. & Artigas, F. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationship to clinical improvement. J Affect Disord. 25, 143–9 (1992).
6. McCloskey, D. J. et al. Selective serotonin reuptake inhibitors: measurement of effect on platelet function. Transl Res. 151, 168–72 (2008).
7. Kraglund, K. L. et al. Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS). Stroke. 49, 2568–76 (2018).
8. Kraglund, K. L., Mortensen, J. K., Grove, E. L., Johnsen, S. P. & Andersen, G. TALOS: A multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke. Int J Stroke. 10, 985–7 (2015).
9. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 348, 1329–39 (1996).
10. Hackam, D. G. & Spence, J. D. Antiplatelet Therapy in Ischemic Stroke and Transient Ischemic Attack. Stroke. 50, 773–8 (2019).
11. Grove, E. L., Storey, R. F. & Würtz, M. Platelet function testing in atherothrombotic disease. Curr Pharm Des. 18, 5379–91 (2012).
12. Grove, E. L. et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost. 103, 1245–53 (2010).
13. Freynhofer, M. K. et al. Antiplatelet drugs in patients with enhanced platelet turnover: Biomarkers versus platelet function testing. Thromb Haemost. 114, 459–68 (2015).
14. Labos, C., Dasgupta, K., Nedjar, H., Turecki, G. & Rahme, E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ. 183, 1835–43 (2011).
15. Li, N., Wallén, N. H., Ladjevardi, M. & Hjemdahl, P. Effects of serotonin on platelet activation in whole blood. Blood Coagul fibrinolysis. 8, 517–23 (1997).
16. Galan, A. M. et al. Serotonergic mechanisms enhance platelet-mediated thrombogenicity. Thromb Haemost. 102, 511–9 (2009).
17. Carneiro, A., Cook, E., Murphy, D. & Blakely, R. Interactions between integrin αIIbβ3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. J Clin Invest. 118, 1544–1552 (2008).
18. Tseng, Y. L. et al. Micromolar concentrations of citalopram or escitalopram inhibit glycoprotein VI-mediated and integrin αIIbβ3-mediated signaling in human platelets. Toxicol Appl Pharmacol. 364, 106–113 (2019).
19. Roweth, H. G. et al. Two novel, putative mechanisms of action for citalopram-induced platelet inhibition. Sci Rep. 8, 16677 (2018).